Peptide, DNA Duo may Help to Combat Autoimmune Disease

by VR Sreeraman on September 17, 2007 at 5:14 PM
Peptide, DNA Duo may Help to Combat Autoimmune Disease

A new research has revealed that a human peptide called LL37, when coupled with body's own DNA, works as a natural antibiotic against invading microbes.

The research team, led by scientists at The University of Texas M. D. Anderson Cancer Center, reported their finding in an early online publication of Nature.


"This combination of the peptide and self-DNA activates the same immune response pathway as a virus does," Nature quoted senior author Michel Gilliet, M.D., assistant professor in M. D. Anderson's Departments of Immunology and Melanoma Medical Oncology, as saying.

According to the researchers, this immune response is both a likely key driver of autoimmune disease and an early warning system that flags tissue damage to launch a protective inflammatory response to injury. "We show that this pathway may drive autoimmunity in psoriasis, a chronic inflammatory skin disease," Gilliet said.

The key peptide is also heavily expressed in other autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis. The key peptide, called LL37 not only provides a new potential target to block in the treatment of constant inflammatory diseases but also acts as a possible component for vaccines against infectious diseases and cancers.

The research team found the new pathway by studying the activation of important immune defense cells in psoriasis. Plasmacytoid dendritic cells (pDCs) are highly specialized to recognize viral and other microbial infections. They engulf a virus and set off an immune system cascade to fight the infection by producing interferons.

The researchers previously showed that pDC activation in psoriatic skin drives the development of human psoriasis. "These dendritic cells normally do not respond to self-DNA," Gilliet explained. Dendritic cells' insensitivity prevents the cells from launching an attack on the body's own tissue.

However, researchers had accumulated evidence of a link between skin damage with release of self-DNA and pDC activation in psoriatic skin leading to disease formation. They lacked a molecular mechanism connecting these factors.

Research involved a series of lab experiments and identified that LL37 as the key ingredient in psoriatic tissue that activates the dendritic cells. The peptide is a member of a family of antimicrobial peptides long known to defend against infection through their ability to directly destroy bacteria and viruses.

The research concluded that LL37 activates the dendritic cells by binding to the self-DNA to form a structure that allows it into the dendritic cells, as if it were an invading microbe.

"We think LL37's normal job is to alert the immune system to tissue damage and stimulate a temporary inflammatory response that enhances resistance to infection and initiates wound healing. When tissue is injured, cells are destroyed and they spill DNA into the areas surrounding the cells. LL37, released by epithelial cells, binds this extracellular DNA, which is then taken up by the pDCs to launch the protective inflammatory immune response," Gilliet said.

Source: ANI
Font : A-A+



Recommended Readings

Latest Research News

South Korea's 2050 Forecast: Negative Growth Amid Low Fertility
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
New Immunotherapy for Psoriasis & Vitiligo
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
2050 Forecast: 1.06 Billion Individuals to Face 'Other' Musculoskeletal Disorders
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.
Gene Therapies Can Disrupt Gaucher Disease Drug Market
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
NASH Cases Expected to Hit 26.55 Million in 7MM by 2032
Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Peptide, DNA Duo may Help to Combat Autoimmune Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests